80
Participants
Start Date
September 30, 2013
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
botulinum toxin A + ropivacaïne
"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
Ropivacaïne
"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
Clinique Axium, Aix-en-Provence
Besançon University Hospital, Besançon
Rennes University Hospital, Rennes
Nantes University Hospital, Nantes
Clermont-Ferrand University Hospital, Clermont-Ferrand
La Réunion University Hospital, Saint Denis de La Réunion
Nantes University Hospital
OTHER